270 related articles for article (PubMed ID: 33876771)
21. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
22. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
23. Imatinib is not a potential alternative treatment for uterine leiomyosarcoma.
Serrano C; Mackintosh C; Herrero D; Martins AS; de Alava E; Hernández T; Pérez-Fontán J; Abad M; Pérez A; Serrano E; Bullón A; Orfao A
Clin Cancer Res; 2005 Jul; 11(13):4977-9; author reply 4979-80. PubMed ID: 16000598
[No Abstract] [Full Text] [Related]
24. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
25. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
26. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
27. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
[TBL] [Abstract][Full Text] [Related]
28. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
29. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
30. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
31. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.
Dall GV; Hamilton A; Ratnayake G; Scott C; Barker H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326717
[TBL] [Abstract][Full Text] [Related]
32. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.
Agaram NP; Zhang L; LeLoarer F; Silk T; Sung YS; Scott SN; Kuk D; Qin LX; Berger MF; Antonescu CR; Singer S
Genes Chromosomes Cancer; 2016 Feb; 55(2):124-30. PubMed ID: 26541895
[TBL] [Abstract][Full Text] [Related]
33. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
[TBL] [Abstract][Full Text] [Related]
34. Genomic alterations in uterine leiomyosarcomas: potential markers for clinical diagnosis and prognosis.
Hu J; Khanna V; Jones M; Surti U
Genes Chromosomes Cancer; 2001 Jun; 31(2):117-24. PubMed ID: 11319799
[TBL] [Abstract][Full Text] [Related]
35. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
36. Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.
Raish M; Khurshid M; Ansari MA; Chaturvedi PK; Bae SM; Kim JH; Park EK; Park DC; Ahn WS
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1173-86. PubMed ID: 22419440
[TBL] [Abstract][Full Text] [Related]
37. Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P; Mughal SS; Sanders MA; Hübschmann D; Chung I; Deeg KI; Wong SH; Rabe S; Hlevnjak M; Zapatka M; Ernst A; Kleinheinz K; Schlesner M; Sieverling L; Klink B; Schröck E; Hoogenboezem RM; Kasper B; Heilig CE; Egerer G; Wolf S; von Kalle C; Eils R; Stenzinger A; Weichert W; Glimm H; Gröschel S; Kopp HG; Omlor G; Lehner B; Bauer S; Schimmack S; Ulrich A; Mechtersheimer G; Rippe K; Brors B; Hutter B; Renner M; Hohenberger P; Scholl C; Fröhling S
Nat Commun; 2018 Jan; 9(1):144. PubMed ID: 29321523
[TBL] [Abstract][Full Text] [Related]
38. Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
Davis LE; Nusser KD; Przybyl J; Pittsenbarger J; Hofmann NE; Varma S; Vennam S; Debiec-Rychter M; van de Rijn M; Davare MA
Mol Cancer Res; 2019 Mar; 17(3):676-685. PubMed ID: 30518629
[TBL] [Abstract][Full Text] [Related]
39. The Functional Role and Regulatory Mechanism of FTO m
Yang Q; Al-Hendy A
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175660
[TBL] [Abstract][Full Text] [Related]
40. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]